Baseline characteristics and outcomes
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Lymphoma characteristics | |||
| Histology | DLBCL | DLBCL | DLBCL |
| Age, y | 40 | 54 | 60 |
| Sex | Female | Male | Male |
| Race | Black | Asian | White |
| ECOG | 1 | 0 | 0 |
| Ann Arbor stage | 4 | 4 | 4 |
| IPI score | 3 | 3 | 3 |
| CD19 status | Positive | Positive | Positive |
| No. of prior therapies | 4 | 2 | 2 |
| Refractory disease | Yes | No | No |
| Previous ASCT | Yes | No | No |
| Conditioning | Flu-Cy | Flu-Cy | Flu-Cy |
| Hepatitis characteristics | |||
| HBsAg | Negative | Positive | Negative |
| HBcAb | Positive | Positive | Negative |
| HBV DNA, IU/mL | <20 | <10 | — |
| HBV NAT | Negative | — | — |
| Anti-HCV | Negative | Negative | Positive |
| HCV RNA, IU/mL | — | — | 15.1 million |
| ALT, U/L | 162 | 12 | 70 |
| Bilirubin total, mg/dL | 0.7 | 0.5 | 0.8 |
| CT evidence of cirrhosis | No | No | No |
| Previous hepatitis | No | Yes | Yes |
| Antiviral therapy | Entecavir | Tenofovir | — |
| Outcomes | |||
| Response | Complete remission | Complete remission | Complete remission |
| Grade 3-4 CRES | Yes | No | Yes |
| Grade 3-4 CRS | No | Yes | Yes |
| Grade 1-2 CRS | Yes | No | No |
| PFS, mo | 31 | 8 | 6 |
| Progressed | No | No | No |
| OS, mo | 31 | 8 | 6 |
| Dead | No | No | No |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Lymphoma characteristics | |||
| Histology | DLBCL | DLBCL | DLBCL |
| Age, y | 40 | 54 | 60 |
| Sex | Female | Male | Male |
| Race | Black | Asian | White |
| ECOG | 1 | 0 | 0 |
| Ann Arbor stage | 4 | 4 | 4 |
| IPI score | 3 | 3 | 3 |
| CD19 status | Positive | Positive | Positive |
| No. of prior therapies | 4 | 2 | 2 |
| Refractory disease | Yes | No | No |
| Previous ASCT | Yes | No | No |
| Conditioning | Flu-Cy | Flu-Cy | Flu-Cy |
| Hepatitis characteristics | |||
| HBsAg | Negative | Positive | Negative |
| HBcAb | Positive | Positive | Negative |
| HBV DNA, IU/mL | <20 | <10 | — |
| HBV NAT | Negative | — | — |
| Anti-HCV | Negative | Negative | Positive |
| HCV RNA, IU/mL | — | — | 15.1 million |
| ALT, U/L | 162 | 12 | 70 |
| Bilirubin total, mg/dL | 0.7 | 0.5 | 0.8 |
| CT evidence of cirrhosis | No | No | No |
| Previous hepatitis | No | Yes | Yes |
| Antiviral therapy | Entecavir | Tenofovir | — |
| Outcomes | |||
| Response | Complete remission | Complete remission | Complete remission |
| Grade 3-4 CRES | Yes | No | Yes |
| Grade 3-4 CRS | No | Yes | Yes |
| Grade 1-2 CRS | Yes | No | No |
| PFS, mo | 31 | 8 | 6 |
| Progressed | No | No | No |
| OS, mo | 31 | 8 | 6 |
| Dead | No | No | No |
—, not applicable; ALT, alanine transferase; ASCT, autologous stem cell transplant; CRES, CAR-related encephalopathy syndrome; CRS, cytokine release syndrome; CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; Flu-Cy, fludarabine and cyclophosphamide; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; IPI, International Prognostic Index; NAT, nucleic acid testing; OS, overall survival; PFS, progression-free survival.